Skip to main content

Free Content Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

Summary Objective 

To assess the efficacy of methylene blue (MB) monotherapy in semi-immune adults with uncomplicated malaria in Burkina Faso. Methods 

In an open-label controlled phase II study with 60 semi-immune adults with uncomplicated falciparum malaria in Nouna, north-western Burkina Faso, MB monotherapy (390 mg twice daily) was given sequentially to groups of 20 adults for 7 days (MB7), 5 days (MB5) and 3 days (MB3), respectively. The primary outcome was the rate of adequate clinical and parasitological response (ACPR) on day 28 of follow-up. Results 

Of the study population, 27/58 (47%) and 5/51 (10%) patients still had parasites on days 2 and 3, respectively, of follow-up resulting in 9/58 (16%) early treatment failures. By day 14, no recrudescence was observed but in 4/19 (MB5) and 2/20 (MB3) individuals by day 28. The PCR-corrected rate of ACPR was 72%, 58% and 85% in groups 7, 5 and 3, respectively, by per protocol analysis. Self-limiting dysuria was the most frequent adverse event. Conclusions 

MB acts slowly against the blood stages of P. falciparum. MB alone needs to be given for at least 7 days to be efficacious in the treatment of falciparum malaria but should be used in combination with a fast acting antimalarial.

French
Communication brève:  Objectif: 

Evaluer l’efficacité du bleu de méthylène (MB) en monothérapie chez des adultes semi-immuns atteints de malaria non compliquée au Burkina-Faso. Méthodes: 

Dans une étude ouverte contrôlée de phase II avec 60 adultes semi-immuns atteints de malaria falciparum non compliquée à Nouna, au nord-ouest du Burkina-Faso, le MB en monothérapie (390 mg deux fois par jour) a été administré de façon séquentielle à des groupes de 20 adultes pendant sept (MB7), cinq (MB5) et trois jours (MB3), respectivement. Le critère principal était le taux de réponses cliniques et parasitologiques adéquates (RCPA) au jour 28 du suivi. Résultats: 

27/58 (47%) et 5/51 (10%) patients avaient encore des parasites respectivement aux jours 2 et 3 du suivi, résultant en 9/58 (16%) échecs précoces de traitement. Au jour 14, aucune recrudescence n’a été observée, mais bien au jour 28 chez 4/19 (MB5) et 2/20 (MB3) personnes. Le taux de RCPA ajusté par les résultats de la PCR était de 72%, 58% et 85% respectivement dans les groupes 7, 5 et 3, selon l’analyse per protocole. La dysurie auto-limitante était l’événement indésirable le plus fréquent. Conclusions: 

Le MB agit lentement contre les stades sanguins de P. MB seul doit être administré pendant au moins 7 jours pour être efficace dans le traitement de la malaria falciparum, mais devrait être utilisé en combinaison avec un antipaludique à action rapide.

Keywords: Africa; Afrique; Burkina Faso; azul de metileno; bleu de méthylène; burkina Faso; burkina-Faso; efficacité; efficacy; eficacia; falciparum malaria; malaria falciparum; malaria por falciparum; methylene blue; África

Document Type: Short Communication

DOI: http://dx.doi.org/10.1111/j.1365-3156.2010.02526.x

Affiliations: 1:  Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso 2:  Institute of Medical Biometry and Informatics, Medical School, Ruprecht-Karls-University, Heidelberg, Germany 3:  Institute of Bioinformatics and Epidemiology, Medical School, Ludwig Maximilians University München, München, Germany 4:  Institute of Tropical Medicine and International Health, Charité– University Medicine Berlin, Berlin, Germany 5:  Department Clinical Pharmacology and Pharmaco-Epidemiology, Medical School, Ruprecht-Karls-University, Heidelberg, Germany 6:  Biochemistry Centre, Ruprecht-Karls-University, Heidelberg, Germany 7:  Institute of Public Health, Medical School, Ruprecht-Karls-University, Heidelberg, Germany

Publication date: June 1, 2010

bsc/tmih/2010/00000015/00000006/art00009
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more